Literature DB >> 8892960

Murine leukemia virus-based Tat-inducible long terminal repeat replacement vectors: a new system for anti-human immunodeficiency virus gene therapy.

P M Cannon1, N Kim, S M Kingsman, A J Kingsman.   

Abstract

We have constructed new murine leukemia virus (MLV)-based vectors (TIN vectors) which, following integration, contain human immunodeficiency virus (HIV) type 1 U3 and R sequences in place of the MLV U3 and R regions. This provides, for the first time, single transcriptional unit retroviral vectors under the control of Tat. TIN vectors have several advantages for anti-HIV gene therapy applications.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8892960      PMCID： PMC190909     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  54 in total

1.  Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line.

Authors:  J P Morgenstern; H Land
Journal:  Nucleic Acids Res       Date:  1990-06-25       Impact factor: 16.971

2.  Quantitative analysis of gene suppression in integrated retrovirus vectors.

Authors:  M Emerman; H M Temin
Journal:  Mol Cell Biol       Date:  1986-03       Impact factor: 4.272

3.  Factors affecting long-term stability of Moloney murine leukemia virus-based vectors.

Authors:  L Xu; J K Yee; J A Wolff; T Friedmann
Journal:  Virology       Date:  1989-08       Impact factor: 3.616

4.  Functional dissection of the HIV-1 Rev trans-activator--derivation of a trans-dominant repressor of Rev function.

Authors:  M H Malim; S Böhnlein; J Hauber; B R Cullen
Journal:  Cell       Date:  1989-07-14       Impact factor: 41.582

5.  Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism.

Authors:  M Emerman; H M Temin
Journal:  Cell       Date:  1984-12       Impact factor: 41.582

6.  Transcriptional interference in avian retroviruses--implications for the promoter insertion model of leukaemogenesis.

Authors:  B R Cullen; P T Lomedico; G Ju
Journal:  Nature       Date:  1984 Jan 19-25       Impact factor: 49.962

7.  Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector.

Authors:  P A Hantzopoulos; B A Sullenger; G Ungers; E Gilboa
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

8.  Determination of the leukaemogenicity of a murine retrovirus by sequences within the long terminal repeat.

Authors:  J Lenz; D Celander; R L Crowther; R Patarca; D W Perkins; W A Haseltine
Journal:  Nature       Date:  1984 Mar 29-Apr 4       Impact factor: 49.962

9.  Trans-activator gene of human T-lymphotropic virus type III (HTLV-III).

Authors:  S K Arya; C Guo; S F Josephs; F Wong-Staal
Journal:  Science       Date:  1985-07-05       Impact factor: 47.728

10.  Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells.

Authors:  S F Yu; T von Rüden; P W Kantoff; C Garber; M Seiberg; U Rüther; W F Anderson; E F Wagner; E Gilboa
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205
View more
  14 in total

1.  Foamy virus envelope glycoprotein-mediated entry involves a pH-dependent fusion process.

Authors:  Marcus Picard-Maureau; Gergely Jarmy; Angelika Berg; Axel Rethwilm; Dirk Lindemann
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

2.  Determinants of high titer in recombinant porcine endogenous retroviruses.

Authors:  Ian Harrison; Yasuhiro Takeuchi; Birke Bartosch; Jonathan P Stoye
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

3.  Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1.

Authors:  V N Kim; K Mitrophanous; S M Kingsman; A J Kingsman
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

4.  Efficient infection mediated by viral receptors incorporated into retroviral particles.

Authors:  J W Balliet; P Bates
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

5.  Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control.

Authors:  Z L Chu; T A McKinsey; L Liu; J J Gentry; M H Malim; D W Ballard
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

6.  XPB mediated retroviral cDNA degradation coincides with entry to the nucleus.

Authors:  Kristine E Yoder; William Roddick; Pia Hoellerbauer; Richard Fishel
Journal:  Virology       Date:  2010-12-17       Impact factor: 3.616

7.  PD 404,182 is a virocidal small molecule that disrupts hepatitis C virus and human immunodeficiency virus.

Authors:  Ana Maria Chamoun; Karuppiah Chockalingam; Michael Bobardt; Rudo Simeon; Jinhong Chang; Philippe Gallay; Zhilei Chen
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

8.  Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses.

Authors:  George Koutsoudakis; Artur Kaul; Eike Steinmann; Stephanie Kallis; Volker Lohmann; Thomas Pietschmann; Ralf Bartenschlager
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

9.  Construction and characterization of a hybrid mouse mammary tumor virus/murine leukemia virus-based retroviral vector.

Authors:  R M Saller; F Oztürk; B Salmons; W H Günzburg
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

10.  Nonreciprocal pseudotyping: murine leukemia virus proteins cannot efficiently package spleen necrosis virus-based vector RNA.

Authors:  J L Certo; B F Shook; P D Yin; J T Snider; W S Hu
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.